封面
市場調查報告書
商品編碼
1463412

全球藥品無菌檢測市場規模、佔有率、成長分析,依類型(內部和外包)、依樣本(藥品、醫療器材)- 2024-2031 年產業預測

Global Pharmaceutical Sterility Testing Market Size, Share, Growth Analysis, By Type(In-house, and Outsourcing), By Sample(Pharmaceuticals, Medical Devices) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年,全球藥品無菌檢測市場規模為14.8億美元,預計將從2023年的16.6億美元成長到2031年的41.0億美元,在預測期內(2024-2031年)複合年成長率為12% 。

對高品質藥品的需求、對藥物安全性和有效性的日益重視以及無菌檢測的監管要求是推動全球藥品無菌檢測市場的主要因素。透過檢查活微生物的存在,藥物無菌測試可確保藥物和其他藥品的功效和安全性。監管機構強制要求進行無菌測試,以確保藥物和其他醫療用品不受微生物污染,這可能會對患者造成嚴重的負面影響。藥品無菌檢測市場主要由三個因素驅動:對高品質藥品的需求、對藥物安全性和有效性的日益重視以及無菌檢測的監管要求。為了確保其安全性和有效性,美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構強制要求所有藥物和醫療產品都經過無菌測試。因此,近年來對藥物無菌測試的需求顯著增加。藥品無菌檢測產業發展的主要障礙是與檢測商品和服務相關的高昂費用。無菌檢測過程複雜且耗時,需要熟練的工人和精密的設備。這可以阻止一些企業進入該行業並限制其擴張。藥品日益複雜化是藥品無菌檢測產業面臨的主要障礙之一。

目錄

執行摘要

  • 市場概況
  • 命運之輪

研究方法論

  • 資訊採購
  • 二手和主要資料來源
  • 市場規模估計
  • 市場假設與限制

母公司市場分析

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進要素
    • 機會
    • 限制
    • 課題

主要市場洞察

  • 技術分析
  • 定價分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 智慧財產權分析
  • 貿易分析
  • 啟動分析
  • 原料分析
  • 創新矩陣
  • 管道產品分析
  • 總體經濟指標
  • 頂級投資分析
  • 成功的關鍵因素
  • 競爭程度

市場動態與展望

  • 市場動態
    • 促進要素
    • 機會
    • 限制
    • 課題
  • 監管環境
  • 波特分析
  • 對未來顛覆的特別見解

依類型分類的全球藥品無菌檢測市場

  • 市場概況
  • 內部
  • 外包

全球藥品無菌檢測市場(依樣本)

  • 市場概況
  • 藥品
  • 醫療設備
  • 和生物製藥

全球藥品無菌檢測市場規模(依地區)

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 拉丁美洲其他地區
  • 中東和非洲 (MEA)
    • 海灣合作理事會國家
    • 南非
    • MEA 的其餘部分

競爭格局

  • 前 5 名企業比較
  • 2021 年關鍵參與者的市場定位
  • 主要市場參與者所採取的策略
  • 最佳制勝策略
  • 近期市集活動
  • 主要公司市佔率(%),2021年

主要公司簡介

  • Charles River Laboratories International, Inc. (US)
  • Eurofins Scientific (Luxembourg)
  • Merck KGaA (Germany)
  • Thermo Fisher Scientific Inc. (US)
  • SGS SA (Switzerland)
  • WuXi AppTec (China)
  • bioMA(C)rieux SA (France)
  • Nelson Laboratories, LLC (US)
  • Pace Analytical Services, LLC (US)
  • Toxikon Corporation (US)
  • Sartorius AG (Germany)
  • STERIS plc (US)
  • Microbac Laboratories, Inc. (US)
  • North American Science Associates, Inc. (US)
  • Gibraltar Laboratories (US)
  • Boston Analytical, Inc. (US)
  • Analytical Lab Group (US)
  • Becton, Dickinson and Company (US)
  • Pacific Biolabs (US)
  • Dynatec Labs (US)
簡介目錄
Product Code: SQMIG35I2168

Global Pharmaceutical Sterility Testing Market size was valued at USD 1.48 billion in 2022 and is poised to grow from USD 1.66 billion in 2023 to USD 4.10 billion by 2031, growing at a CAGR of 12% during the forecast period (2024-2031).

The need for high-quality pharmaceutical goods, the growing emphasis on drug safety and efficacy, and the regulatory requirements for sterility testing are the main factors driving the global pharmaceutical sterility testing market. By checking for the presence of live microorganisms, pharmaceutical sterility testing ensures the efficacy and safety of medications and other pharmaceutical items. Regulatory bodies mandate sterility testing to guarantee that medications and other medical supplies are free of microbiological contamination, which can have grave negative consequences on patients. The market for pharmaceutical sterility testing is primarily driven by three factors: the need for high-quality pharmaceutical goods, the growing emphasis on drug safety and efficacy, and the regulatory requirements for sterility testing. To guarantee its safety and effectiveness, regulatory bodies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate that all medications and medical products undergo sterility testing. Consequently, there has been a notable surge in the need for pharmaceutical sterility testing in recent times. The primary impediment to the growth of the pharmaceutical sterility testing industry is the exorbitant expenses associated with testing goods and services. The process of sterility testing is intricate and time-consuming, requiring skilled workers and sophisticated equipment. This can prevent some businesses from entering the industry and restrict its expansion. The growing complexity of pharmaceutical goods is one of the main obstacles facing the pharmaceutical sterility testing sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Sterility Testing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceutical Sterility Testing Market Segmental Analysis

The global pharmaceutical sterility testing market is segmented on the basis of type, application, and region. Based on type, the market is segmented into in-house, and outsourcing. In terms of sample, the market is grouped into pharmaceuticals, medical devices, and biopharmaceuticals. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Pharmaceutical Sterility Testing Market

Because biologics and biosimilar medications are so successful in treating critical illnesses including cancer, neurological conditions, and infectious diseases, there has been a surge in demand for these medications in recent years. As a result, there is a growing need for pharmaceutical sterility testing to guarantee the security and effectiveness of these goods. The market for pharmaceutical sterility testing has expanded as a result of the approval of multiple biosimilar medications in recent years, including Adalimumab, Rituximab, and Trastuzumab.

Restraints in the Global Pharmaceutical Sterility Testing Market

Many clients may find the high expense of pharmaceutical sterility testing services to be a major deterrent, particularly in developing nations or environments with limited resources. In order to meet FDA standards, small and medium-sized pharmaceutical and medical device firms prefer to outsource sterility testing because they may not have the resources to perform high-quality tests.

Market Trends of the Global Pharmaceutical Sterility Testing Market

The pharmaceutical industry is seeing an increase in the use of quick microbial detection technologies due to their ability to expedite results and reduce testing durations. It is expected that this trend will continue in the years to come.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Pharmaceutical Sterility Testing Market by Type

  • Market Overview
  • In-house
  • and Outsourcing

Global Pharmaceutical Sterility Testing Market by Sample

  • Market Overview
  • Pharmaceuticals
  • Medical Devices
  • and Biopharmaceuticals

Global Pharmaceutical Sterility Testing Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Charles River Laboratories International, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eurofins Scientific (Luxembourg)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SGS SA (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • WuXi AppTec (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • bioMA(C)rieux SA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nelson Laboratories, LLC (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pace Analytical Services, LLC (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Toxikon Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sartorius AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • STERIS plc (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Microbac Laboratories, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • North American Science Associates, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gibraltar Laboratories (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boston Analytical, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Analytical Lab Group (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Becton, Dickinson and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pacific Biolabs (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dynatec Labs (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments